June 13 (Reuters) - Anne Wojcicki is set to regain

control of 23andMe after a $305 million bid from a nonprofit she

controls topped Regeneron Pharmaceuticals' ( REGN ) offer for

the DNA-testing company in a bankruptcy auction.

Last month, Regeneron agreed to buy the firm for $256

million, topping a $146 million bid from Wojcicki and the

non-profit TTAM Research Institute.

The deal is expected to close in the coming weeks after a

court hearing currently scheduled for June 17, the company said

on Friday.

Once a trailblazer in ancestry DNA testing, 23andMe filed

for bankruptcy in March, seeking to sell its business at auction

after a decline in demand and a 2023 data breach that exposed

sensitive genetic and personal information of millions of

customers.

TTAM said on Friday it would uphold 23andMe's existing

privacy policies and comply with all applicable data protection

laws.

Earlier this week, New York and more than two dozen other

U.S. states sued 23andMe to challenge the sale of its customers'

private information.

The U.S. Bankruptcy Court for the Eastern District of

Missouri oversaw the bidding process.

Regeneron had said it was willing to make a new bid, but

wanted a $10 million breakup fee if Wojcicki's bid is ultimately

accepted.